viewNabriva Therapeutics Plc

Nabriva Therapeutics shares take-off on pneumonia drug trial success

Community-acquired bacterial pneumonia, or CABP is a leading cause of infectious death and that the trial has provided “strong evidence” of the potential of its drug, called Lefamulin.

Trader pointing up
Nabriva shares were seen as much as 100% higher

Nabriva Therapeutics Plc (NASDAQ:NBRV) shares were seen higher on Monday after the drug developer revealed positive results for a Phase 3 drug trial of a potential treatment for community-acquired bacterial pneumonia (CABP).

The company, in a statement, highlighted that CABP is the leading cause of infectious death in the United States and that the trial has provided “strong evidence” of the potential of its drug, called Lefamulin.

The drug met the US Food and Drug Administration (FDA) primary endpoint of non-inferiority compared to current treatment moxifloxacin, and it added that early clinical response (ECR) rates were 87.3% for lefamulin and 90.2% for moxifloxacin.

Dr Colin Broom, Nabriva chief executive, said: “These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen.”

“Due to lefamulin’s flexible dosing and targeted spectrum of activity against the pathogens most commonly associated with CABP, including multidrug-resistant strains, we believe that lefamulin is well suited to be a first-line empiric monotherapy.”

Nabriva is separately advancing another trial which is due to complete enrolment in the fourth quarter, with topline results anticipated by spring 2018.

Bloom added: “I am extremely proud and appreciative of the Nabriva Therapeutics team that has advanced lefamulin, which has the potential to be the first in a new class of antibiotics for CABP in more than 15 years, from initial discovery in our labs to this important milestone.

Later in the day, shares added almost 42% to US$9.74.

Quick facts: Nabriva Therapeutics Plc

Price: 1.77 USD

Market: NASDAQ
Market Cap: $138.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



discoverIE Group CEO talks strategy, focus on growth markets and future...

discoverIE Group PLC's (LON:DSCV) Nick Jefferies says the company's strategy is very simple and has been the same for over ten years. ''We aim to grow revenue ahead of GDP and we aim to do that by focusing on growth target markets, we aim to increase our operating  margins by buying more...

1 hour, 32 minutes ago

2 min read